Table 1.
Characteristics of oncology interventional clinical trials according to sponsor type and age of eligibility
| Characteristic | All oncology trials b (n = 18 431) | Trials that only include patients ≥ 18 y (n = 16 625) | Trials that include patients < 18 y (n = 1806) | ||||
|---|---|---|---|---|---|---|---|
| Industry Sponsored (n = 5479) | Non‐Industry Sponsors (n = 11 146) | P‐value | Industry sponsored (n = 299) | Non‐industry sponsors (n = 1507) | P‐value | ||
| Trial phase (%) b | <.001 | <.001 | |||||
| Phase I | 34.7 | 38.7 | 32.1 | 24.2 | 38.4 | ||
| Phase I/II | 13.4 | 14.7 | 12.5 | 19.9 | 11.4 | ||
| Phase II | 40.5 | 28.5 | 48.4 | 35.7 | 41.1 | ||
| Phase III | 9.6 | 16.9 | 4.9 | 18.1 | 7.3 | ||
| Phase IV | 1.8 | 1.3 | 2.1 | 2.2 | 1.8 | ||
|
Mean Trial Duration (y) c (SD) |
3.7 (2.2) | 3.3 (2.0) | 4.0 (2.3) | <.001 | 3.4 (2.1) | 4.5 (2.4) | <.001 |
| Median enrollment (n) d (Interquartile range) | 36 (13‐100.5) | 100 (36‐278) | 24 (10‐53) | <.001 | 43 (22‐114.5) | 28.5 (10.5‐67) | .002 |
| Trial status (%) e | <.001 | .32 | |||||
| Recruiting | 30.8 | 23.0 | 33.5 | 31.3 | 38.9 | ||
| Not recruiting | 0.1 | 0.1 | 0.2 | 0.0 | 0.1 | ||
| Completed | 46.9 | 57.4 | 42.5 | 47.2 | 40.6 | ||
| Terminated | 17.5 | 16.9 | 18.1 | 16.7 | 15.6 | ||
| Withdrawn | 4.0 | 2.3 | 5.0 | 4.1 | 3.7 | ||
| Enroll by invitation | 0.7 | 0.4 | 0.8 | 0.8 | 1.1 | ||
| Results Reported (%) | <.001 | .005 | |||||
| Yes | 24.1 | 25.8 | 23.3 | 28.1 | 20.7 | ||
a
Variables with proportional data show proportions sum within columns.
b
Data for trial phase available in 14 731 trials.
c
Trial duration calculated as time from study start to study completion date only for completed trials with available duration data (n = 6736).
d
Trial enrollment calculated only for completed trials with results reported (n = 4839).
e
Data for trial status available in 14 428 trials.